Business
Board Change
Board Change.
About this update from Futura Medical Plc
[{"type":"text","content":"\n\n \n18 July 2023\nJeff Needham to succeed John Clarke as Non-Executive\nChairman of Futura Medical plc\n \nFutura Medical plc (AIM: FUM) (\"Futura\" or the \"Company\"), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology focused on sexual health, announces that Non-Executive Chairman, John Clarke has stepped down and is succeeded by existing Non-Executive board member, Jeff Needham.\nJohn joined Futura on 1 November 2011 and has been instrumental in driving the Company's strategy and success in securing commercial partnerships. His departure is part of a planned transition with Independent Non-Executive Director, Jeff succeeding John as Chairman. Jeff has been a Non-Executive Director of the Company since October 2021. A search for a new Non-Executive Director is underway and an announcement will be made in due course. The Company continues its progress in a pivotal year of success in broadening the distribution and availability of MED3000 across different markets, worldwide.\nJames Barder, Chief Executive Officer of Futura, said: \"John has been an outstanding leader and has been instrumental in shaping the growth of Futura since his appointment. On behalf of the board and the Futura team I would like to thank him for his significant contributions and critical guidance and leadership. We wish John all the best for the future and in his new roles elsewhere. As the commercialisation of MED3000 continues to gather pace in the US and globally, we are fortunate to have a natural successor on the board. Jeff's extensive experience and expertise with the consumer healthcare products industry, in particular in the US market, will be invaluable as Futura enters an exciting new chapter in its development.\"\n \nJohn Clarke, departing Chairman of Futura, commented: \"Following yesterday's announcement of the Company's US collaboration with global leading consumer healthcare company, Haleon, and as the Company enters its next stage of growth, it is the appropriate time for me, after twelve years to move on. It has been a privilege to work with the Futura team, seeing transformational progress, growth and execution. Achieving FDA approval for our lead product MED3000 was a critical focus for me as Chairman, significantly de-risking...